Obesity Market's Expanding Girth
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' Acomplia (rimonabant) and Alizyme's ATL-962 are key pipeline products that could have a combined 70% share of the obesity market by 2012, Datamonitor predicts in a July 9 report reviewing 22 compounds in development